Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethylene Glycol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL1879522 | 1.00 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| Ethylene Glycol SCHEMBL8333223 | 1.00 | TSHR (0.46) | TSHRALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| Ethylene Glycol SCHEMBL1115046 | 0.96 | TSHR (0.43) | TSHRALDH1A1SMN1; SMN2 | |
| Ethylene Glycol SCHEMBL3171689 | 0.92 | TSHR (0.46) | TSHRALDH1A1 | |
| Ethylene Glycol SCHEMBL622577 | 0.92 | TSHR (0.46) | TSHRALDH1A1 | |
| Ethylene Glycol SCHEMBL4769225 | 0.92 | TSHR (0.46) | TSHRALDH1A1 | |
| Ethylene Glycol SCHEMBL9756248 | 0.92 | TSHR (0.46) | TSHRALDH1A1 | |
| Ethylene Glycol SCHEMBL5830392 | 0.92 | TSHR (0.46) | TSHRALDH1A1 | |
| Ethylene Glycol SCHEMBL3200076 | 0.92 | TSHR (0.46) | TSHRALDH1A1 | |
| Ethylene Glycol SCHEMBL3197361 | 0.92 | TSHR (0.46) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021080527-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING DIFLUOCORTOLONE AND ISOCONAZOLE | PHARMACTİVE İLAÇ SANAYİ VE TİCARET A.Ş. (TR) | 2021-04-29 | — | — | WO | claimed |
| CN-103502386-B | Viscoelastic fluid of thickening and application thereof | 阿克佐诺贝尔化学国际公司 | 2017-03-08 | — | — | CN | claimed |
| US-9341052-B2 | Thickened viscoelastic fluids and uses thereof | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2016-05-17 | — | — | US | claimed |
| EP-1361864-B9 | LIQUID SPRAY FORMULATIONS FOR BUCCAL DELIVERY OF CANNABINOIDS | GW PHARMA LTD (GB) | 2014-07-09 | — | — | EP | claimed |
| US-20140076572-A1 | Thickened viscoelastic fluids and uses thereof | AKZO NOBEL CHEMICALS INTERNATIONAL B.V. (NL) | 2014-03-20 | — | — | US | claimed |
| CN-103502386-A | Thickened viscoelastic fluids and uses thereof | AKZO NOBEL CHEMICALS INT BV | 2014-01-08 | — | — | CN | claimed |
| EP-1361864-B1 | LIQUID SPRAY FORMULATIONS FOR BUCCAL DELIVERY OF CANNABINOIDS | GW PHARMA LTD (GB) | 2013-12-04 | — | — | EP | claimed |
| EP-0734257-B1 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING (S)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID | ZAMBON SPA (IT) | 2002-03-06 | — | — | EP | claimed |
| EP-0734257-A1 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING (S)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID | ZAMBON GROUP S.p.A. (IT) | 1996-10-02 | — | — | EP | claimed |
| WO-1995016445-A1 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING (S)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID | ZAMBON GROUP S.P.A. (IT) | 1995-06-22 | — | — | WO | claimed |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-11844861-B2 | Topical Montelukast formulations | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2023-12-19 | — | — | US | disclosed |
| US-11793763-B2 | Water-soluble lutein ester microcapsules and a method of preparing the same | HENAN ZHONGDA HENGYUAN BIOTECHNOLOGY STOCK CO., LTD. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-20230277449-A1 | ORAL CAVITY POLYMERIC DELIVERY SYSTEMS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-09-07 | — | — | US | disclosed |
| EP-4181875-A1 | ORAL CAVITY POLYMERIC DELIVERY SYSTEMS | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2023-05-24 | — | — | EP | disclosed |
| WO-1995016445-A1 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING (S)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID | ZAMBON GROUP S.P.A. (IT) | 1995-06-22 | — | — | WO | disclosed |
| WO-1995016445-A1 | PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING (S)-2-(4-ISOBUTYLPHENYL)PROPIONIC ACID | ZAMBON GROUP S.P.A. (IT) | 1995-06-22 | — | — | WO | disclosed |
| US-5385938-A | application of mixtures containing hydroxyacetic acid(or its salts) to skin | IGI, INC. | 1995-01-31 | — | — | US | disclosed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | disclosed |
| EP-0413528-A1 | Amphoteric compositions and polymeric forms of alpha hydroxyacids, and their therapeutic use | Yu, Ruey J., Dr. (US) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844861-B2 | Topical Montelukast formulations | CYSLTR1, CYSLTR2, SYMPK | TSHR 4858/4885ALDH1A1 1652/4885SMN1; SMN2 4098/4885 |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | MAPKAPK2, MAP4K2, MAPK1 | TSHR 3588/4885ALDH1A1 1266/4885SMN1; SMN2 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.